Herpes simplex virus amplicon delivery of a hypoxia-inducible angiogenic inhibitor blocks capillary formation in hepatocellular carcinoma

Richard H. Pin, Maura Reinblatt, William J. Bowers, Howard J. Federoff, Yuman Fong, S. Vickers, M. Callery

Research output: Contribution to journalArticle

Abstract

Tumor hypoxia induces vascular endothelial growth factor (VEGF) expression, which stimulates tumor angiogenesis. The VEGF pathway is inhibited by soluble VEGF receptors (soluble fetal liver kinase-1 [sFlk-1]) that bind VEGF and block its interaction with endothelial cells. Herpes simplex virus (HSV)-derived amplicons are replication-incompetent viruses used for gene delivery. We attempt to attenuate angiogenesis and inhibit hepatoma growth through amplicon-mediated expression of sFlk-1 under hypoxic control. A multimerized hypoxia-responsive enhancer (10xHRE) was cloned upstream of the sFlk-1 gene (10xHRE/sFlk-1). An amplicon expressing 10xHRE/sFlk-1 was genetically engineered (HSV10xHRE/sFlk-1). SK-HEP-1 human hepatoma cells were transduced with HSV10xHRE/sFlk-1 and incubated in normoxia (21% O2) or hypoxia (1% O2). Human umbilical vein endothelial cell assay evaluated capillary inhibition. Western blot assessed sFlk-1 expression. SK-HEP-1 flank tumors (n = 24) in athymic mice were treated with HSV10xHRE/sFlk-1. Media from hypoxic SK-HEP-1 transduced with HSV10xHRE/sFlk-1 yielded an 80% reduction in capillary formation (P <0.005), whereas normoxic SK-HEP-1 yielded a 25% reduction (P <0.05). Western blot of SK-HEP-1 transduced with HSV10xHRE/sFlk-1 demonstrated greater sFlk-1 expression in hypoxia vs. normoxia. SK-HEP-1 tumors treated with HSV10xHRE/sFlk-1 yielded a 72% reduction in volume vs. the control group (P <0.000001). HSV amplicon-mediated delivery of a hypoxia-inducible soluble VEGF receptor substantially reduces new vessel formation and tumor growth in hepatoma.

Original languageEnglish (US)
Pages (from-to)812-823
Number of pages12
JournalJournal of Gastrointestinal Surgery
Volume8
Issue number7
DOIs
StatePublished - 2004
Externally publishedYes

Fingerprint

Vascular Endothelial Growth Factor Receptor-2
Angiogenesis Inhibitors
Simplexvirus
Hepatocellular Carcinoma
Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factor Receptor
Neoplasms
Hypoxia
Western Blotting
Genes
Human Umbilical Vein Endothelial Cells
Virus Replication
Growth
Nude Mice
Endothelial Cells

Keywords

  • Flk-1
  • Gene therapy
  • Herpes simplex virus
  • Hypoxia-inducible factor 1
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Surgery

Cite this

Herpes simplex virus amplicon delivery of a hypoxia-inducible angiogenic inhibitor blocks capillary formation in hepatocellular carcinoma. / Pin, Richard H.; Reinblatt, Maura; Bowers, William J.; Federoff, Howard J.; Fong, Yuman; Vickers, S.; Callery, M.

In: Journal of Gastrointestinal Surgery, Vol. 8, No. 7, 2004, p. 812-823.

Research output: Contribution to journalArticle

Pin, Richard H. ; Reinblatt, Maura ; Bowers, William J. ; Federoff, Howard J. ; Fong, Yuman ; Vickers, S. ; Callery, M. / Herpes simplex virus amplicon delivery of a hypoxia-inducible angiogenic inhibitor blocks capillary formation in hepatocellular carcinoma. In: Journal of Gastrointestinal Surgery. 2004 ; Vol. 8, No. 7. pp. 812-823.
@article{cac613386e014f9da8d8fd0019f4cfd5,
title = "Herpes simplex virus amplicon delivery of a hypoxia-inducible angiogenic inhibitor blocks capillary formation in hepatocellular carcinoma",
abstract = "Tumor hypoxia induces vascular endothelial growth factor (VEGF) expression, which stimulates tumor angiogenesis. The VEGF pathway is inhibited by soluble VEGF receptors (soluble fetal liver kinase-1 [sFlk-1]) that bind VEGF and block its interaction with endothelial cells. Herpes simplex virus (HSV)-derived amplicons are replication-incompetent viruses used for gene delivery. We attempt to attenuate angiogenesis and inhibit hepatoma growth through amplicon-mediated expression of sFlk-1 under hypoxic control. A multimerized hypoxia-responsive enhancer (10xHRE) was cloned upstream of the sFlk-1 gene (10xHRE/sFlk-1). An amplicon expressing 10xHRE/sFlk-1 was genetically engineered (HSV10xHRE/sFlk-1). SK-HEP-1 human hepatoma cells were transduced with HSV10xHRE/sFlk-1 and incubated in normoxia (21{\%} O2) or hypoxia (1{\%} O2). Human umbilical vein endothelial cell assay evaluated capillary inhibition. Western blot assessed sFlk-1 expression. SK-HEP-1 flank tumors (n = 24) in athymic mice were treated with HSV10xHRE/sFlk-1. Media from hypoxic SK-HEP-1 transduced with HSV10xHRE/sFlk-1 yielded an 80{\%} reduction in capillary formation (P <0.005), whereas normoxic SK-HEP-1 yielded a 25{\%} reduction (P <0.05). Western blot of SK-HEP-1 transduced with HSV10xHRE/sFlk-1 demonstrated greater sFlk-1 expression in hypoxia vs. normoxia. SK-HEP-1 tumors treated with HSV10xHRE/sFlk-1 yielded a 72{\%} reduction in volume vs. the control group (P <0.000001). HSV amplicon-mediated delivery of a hypoxia-inducible soluble VEGF receptor substantially reduces new vessel formation and tumor growth in hepatoma.",
keywords = "Flk-1, Gene therapy, Herpes simplex virus, Hypoxia-inducible factor 1, Vascular endothelial growth factor",
author = "Pin, {Richard H.} and Maura Reinblatt and Bowers, {William J.} and Federoff, {Howard J.} and Yuman Fong and S. Vickers and M. Callery",
year = "2004",
doi = "10.1016/j.gassur.2004.08.007",
language = "English (US)",
volume = "8",
pages = "812--823",
journal = "Journal of Gastrointestinal Surgery",
issn = "1091-255X",
publisher = "Springer New York",
number = "7",

}

TY - JOUR

T1 - Herpes simplex virus amplicon delivery of a hypoxia-inducible angiogenic inhibitor blocks capillary formation in hepatocellular carcinoma

AU - Pin, Richard H.

AU - Reinblatt, Maura

AU - Bowers, William J.

AU - Federoff, Howard J.

AU - Fong, Yuman

AU - Vickers, S.

AU - Callery, M.

PY - 2004

Y1 - 2004

N2 - Tumor hypoxia induces vascular endothelial growth factor (VEGF) expression, which stimulates tumor angiogenesis. The VEGF pathway is inhibited by soluble VEGF receptors (soluble fetal liver kinase-1 [sFlk-1]) that bind VEGF and block its interaction with endothelial cells. Herpes simplex virus (HSV)-derived amplicons are replication-incompetent viruses used for gene delivery. We attempt to attenuate angiogenesis and inhibit hepatoma growth through amplicon-mediated expression of sFlk-1 under hypoxic control. A multimerized hypoxia-responsive enhancer (10xHRE) was cloned upstream of the sFlk-1 gene (10xHRE/sFlk-1). An amplicon expressing 10xHRE/sFlk-1 was genetically engineered (HSV10xHRE/sFlk-1). SK-HEP-1 human hepatoma cells were transduced with HSV10xHRE/sFlk-1 and incubated in normoxia (21% O2) or hypoxia (1% O2). Human umbilical vein endothelial cell assay evaluated capillary inhibition. Western blot assessed sFlk-1 expression. SK-HEP-1 flank tumors (n = 24) in athymic mice were treated with HSV10xHRE/sFlk-1. Media from hypoxic SK-HEP-1 transduced with HSV10xHRE/sFlk-1 yielded an 80% reduction in capillary formation (P <0.005), whereas normoxic SK-HEP-1 yielded a 25% reduction (P <0.05). Western blot of SK-HEP-1 transduced with HSV10xHRE/sFlk-1 demonstrated greater sFlk-1 expression in hypoxia vs. normoxia. SK-HEP-1 tumors treated with HSV10xHRE/sFlk-1 yielded a 72% reduction in volume vs. the control group (P <0.000001). HSV amplicon-mediated delivery of a hypoxia-inducible soluble VEGF receptor substantially reduces new vessel formation and tumor growth in hepatoma.

AB - Tumor hypoxia induces vascular endothelial growth factor (VEGF) expression, which stimulates tumor angiogenesis. The VEGF pathway is inhibited by soluble VEGF receptors (soluble fetal liver kinase-1 [sFlk-1]) that bind VEGF and block its interaction with endothelial cells. Herpes simplex virus (HSV)-derived amplicons are replication-incompetent viruses used for gene delivery. We attempt to attenuate angiogenesis and inhibit hepatoma growth through amplicon-mediated expression of sFlk-1 under hypoxic control. A multimerized hypoxia-responsive enhancer (10xHRE) was cloned upstream of the sFlk-1 gene (10xHRE/sFlk-1). An amplicon expressing 10xHRE/sFlk-1 was genetically engineered (HSV10xHRE/sFlk-1). SK-HEP-1 human hepatoma cells were transduced with HSV10xHRE/sFlk-1 and incubated in normoxia (21% O2) or hypoxia (1% O2). Human umbilical vein endothelial cell assay evaluated capillary inhibition. Western blot assessed sFlk-1 expression. SK-HEP-1 flank tumors (n = 24) in athymic mice were treated with HSV10xHRE/sFlk-1. Media from hypoxic SK-HEP-1 transduced with HSV10xHRE/sFlk-1 yielded an 80% reduction in capillary formation (P <0.005), whereas normoxic SK-HEP-1 yielded a 25% reduction (P <0.05). Western blot of SK-HEP-1 transduced with HSV10xHRE/sFlk-1 demonstrated greater sFlk-1 expression in hypoxia vs. normoxia. SK-HEP-1 tumors treated with HSV10xHRE/sFlk-1 yielded a 72% reduction in volume vs. the control group (P <0.000001). HSV amplicon-mediated delivery of a hypoxia-inducible soluble VEGF receptor substantially reduces new vessel formation and tumor growth in hepatoma.

KW - Flk-1

KW - Gene therapy

KW - Herpes simplex virus

KW - Hypoxia-inducible factor 1

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=16644370354&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16644370354&partnerID=8YFLogxK

U2 - 10.1016/j.gassur.2004.08.007

DO - 10.1016/j.gassur.2004.08.007

M3 - Article

C2 - 15531234

AN - SCOPUS:16644370354

VL - 8

SP - 812

EP - 823

JO - Journal of Gastrointestinal Surgery

JF - Journal of Gastrointestinal Surgery

SN - 1091-255X

IS - 7

ER -